| 000 | 01689 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250518100112.0 | ||
| 264 | 0 | _c20210514 | |
| 008 | 202105s 0 0 eng d | ||
| 022 | _a1365-2133 | ||
| 024 | 7 |
_a10.1111/bjd.19147 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPaller, A S | |
| 245 | 0 | 0 |
_aEfficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). _h[electronic resource] |
| 260 |
_bThe British journal of dermatology _c08 2020 |
||
| 300 |
_a231-241 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 |
_aDermatologic Agents _xadverse effects |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aEtanercept |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aPsoriasis _xdrug therapy |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aSeyger, M M B | |
| 700 | 1 | _aAlejandro Magariños, G | |
| 700 | 1 | _aBagel, J | |
| 700 | 1 | _aPinter, A | |
| 700 | 1 | _aCather, J | |
| 700 | 1 | _aKeller, S | |
| 700 | 1 | _aRodriguez Capriles, C | |
| 700 | 1 | _aGontijo Lima, R | |
| 700 | 1 | _aGallo, G | |
| 700 | 1 | _aLittle, C A | |
| 700 | 1 | _aEdson-Heredia, E | |
| 700 | 1 | _aLi, L | |
| 700 | 1 | _aXu, W | |
| 700 | 1 | _aPapp, K | |
| 773 | 0 |
_tThe British journal of dermatology _gvol. 183 _gno. 2 _gp. 231-241 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/bjd.19147 _zAvailable from publisher's website |
| 999 |
_c30882503 _d30882503 |
||